Inozyme Pharma financials at a glance

The revenue of Inozyme Pharma is reported as 0 billion Dollars in the fiscal year 2023. The earnings were -1.31 Dollars per share in 2023, which was 25.83 higher than 2021. And about -0.07034 billion Dollars are reported as free cash flow in the financials of Inozyme Pharma 2023. No dividends were paid to the shareholders of the Inozyme Pharma stock NasdaqGS:INZY in the financial year 2023.